EA202190914A1 - Иммуногенные композиции - Google Patents

Иммуногенные композиции

Info

Publication number
EA202190914A1
EA202190914A1 EA202190914A EA202190914A EA202190914A1 EA 202190914 A1 EA202190914 A1 EA 202190914A1 EA 202190914 A EA202190914 A EA 202190914A EA 202190914 A EA202190914 A EA 202190914A EA 202190914 A1 EA202190914 A1 EA 202190914A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunogenic compositions
omv
patient
composition
provides
Prior art date
Application number
EA202190914A
Other languages
English (en)
Russian (ru)
Inventor
Марио КОНТОРНИ
Марияграциа Пицца
Аня Сеуберт
Original Assignee
Глаксосмитклайн Байолоджикалс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс Са filed Critical Глаксосмитклайн Байолоджикалс Са
Publication of EA202190914A1 publication Critical patent/EA202190914A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA202190914A 2018-11-06 2019-11-04 Иммуногенные композиции EA202190914A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18204691 2018-11-06
PCT/EP2019/080120 WO2020094580A1 (en) 2018-11-06 2019-11-04 Immunogenic compositions

Publications (1)

Publication Number Publication Date
EA202190914A1 true EA202190914A1 (ru) 2021-08-03

Family

ID=64456746

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190914A EA202190914A1 (ru) 2018-11-06 2019-11-04 Иммуногенные композиции

Country Status (14)

Country Link
US (2) US12128094B2 (enExample)
EP (1) EP3876982A1 (enExample)
JP (1) JP7469302B2 (enExample)
KR (1) KR102852282B1 (enExample)
CN (1) CN112996538B (enExample)
AR (1) AR117191A1 (enExample)
AU (1) AU2019376832B2 (enExample)
BR (1) BR112021007668A2 (enExample)
CA (1) CA3117867A1 (enExample)
EA (1) EA202190914A1 (enExample)
IL (1) IL282753B2 (enExample)
MX (1) MX2021005303A (enExample)
SG (1) SG11202103389WA (enExample)
WO (1) WO2020094580A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240082379A1 (en) 2020-12-11 2024-03-14 Glaxosmithkline Biologicals Sa Hyper-Blebbing Bacteria
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DE60039450D1 (de) 1999-12-02 2008-08-21 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES3018133T3 (en) * 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
BR112014014950B1 (pt) * 2011-12-21 2022-03-29 Bionet-Asia, Co. Ltd Cepa de bordetella pertussis geneticamente modificada, e, métodos para produzir uma cepa de bordetella pertussis modificada e para produzir antígenos de bordetella pertussis
RU2015106791A (ru) * 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
AR090538A1 (es) * 2013-03-27 2014-11-19 Consejo Nac Invest Cient Tec Vacuna para la prevencion de infecciones con bordetella
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
JP2020500552A (ja) * 2016-11-23 2020-01-16 グリットストーン オンコロジー インコーポレイテッド 新生抗原のウイルスによる送達方法
ES2992907T3 (en) 2017-03-13 2024-12-19 Intravacc B V Bordetella vaccines comprising lps with reduced reactogenicity

Also Published As

Publication number Publication date
AU2019376832B2 (en) 2024-01-25
IL282753A (en) 2021-06-30
CA3117867A1 (en) 2020-05-14
MX2021005303A (es) 2021-07-07
JP2022506347A (ja) 2022-01-17
US20230201325A1 (en) 2023-06-29
US20250049906A1 (en) 2025-02-13
CN112996538B (zh) 2025-07-08
US12128094B2 (en) 2024-10-29
KR102852282B1 (ko) 2025-09-01
IL282753B2 (en) 2025-04-01
JP7469302B2 (ja) 2024-04-16
AU2019376832A1 (en) 2021-05-13
KR20210090646A (ko) 2021-07-20
SG11202103389WA (en) 2021-05-28
EP3876982A1 (en) 2021-09-15
BR112021007668A2 (pt) 2021-07-27
AR117191A1 (es) 2021-07-21
IL282753B1 (en) 2024-12-01
CN112996538A (zh) 2021-06-18
WO2020094580A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
EA202190914A1 (ru) Иммуногенные композиции
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
AR092896A1 (es) Composiciones inmunogenicas
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
TW200719912A (en) Porcine circovirus and helicobacter combination vaccines and methods of use
MD20210028A2 (ro) Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
EA201690115A1 (ru) Комбинированные иммуногенные композиции
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
WO2022150719A3 (en) Antigenic composition(s) and method(s) against porphyromonas gingivalis for the prevention and/or treatment of infection and/or diseases
MX2025006896A (es) Composiciones inmunogenicas y metodos para provocar una respuesta inmunitaria contra clostridioides (clostridium) difficile
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
MX2016016080A (es) Vacunas guiadas por anticuerpos y metodos de uso para generar respuestas imunitarias maduras rapidas.
MX2022012527A (es) Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria.
ZA202400113B (en) Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations
BR112023024546A2 (pt) Métodos de tratamento usando peptídeos imunogênicos
PH12022552239A1 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
PH12022552300A1 (en) Cpg-adjuvanted sars-cov-2 virus vaccine
BR112023017200A2 (pt) Composições orais e uso das mesmas na vacinação
AR053661A1 (es) Peptido para entregar vacunas via mucosas
BR112021017691A2 (pt) Formulações imunogênicas para o tratamento do câncer
GEAP202515919A (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof